IPO Year: 2024
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/21/2025 | $60.00 | Buy | BTIG Research |
2/25/2025 | $50.00 → $55.00 | Overweight → Neutral | Analyst |
2/12/2025 | Outperform → Mkt Perform | William Blair | |
2/5/2025 | $58.00 → $74.00 | Buy | TD Cowen |
12/13/2024 | $60.00 | Outperform | Wolfe Research |
12/9/2024 | $74.00 | Buy | Guggenheim |
11/11/2024 | $45.00 → $65.00 | Buy → Hold | Stifel |
10/2/2024 | $45.00 → $60.00 | Buy → Neutral | BofA Securities |
8/12/2024 | $40.00 | Neutral | Piper Sandler |
7/9/2024 | $41.00 | Buy | BofA Securities |
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services Announced multi-year, strategic collaborations with AstraZeneca and Pathos to work together to build the largest multimodal foundation model in oncology, resulting in additional $200.0 million in data licensing and model development fees over the next
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 5, 2025 /PRNewswire/ --The integration of artificial intelligence (AI) into healthcare is here to stay, and adoption is accelerating. According to research from PYMNTS Intelligence which polled C-suite executives at healthcare companies generating at least $1 billion in annual revenue, 90% already see positive ROI from investments in generative AI (GenAI). Analysts are projecting that by 2035 the gross value added by AI to the healthcare industry will be $461 billion on top of a baseline $2.26 trillion. Behind the scenes, several new AI healthcare tech developments are taking place, with updates rec
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an AI-powered clinical assistant to aid psychiatrists in generating progress notes. Notetaker, which is available in Tempus Hub, ambiently records patient sessions to generate transcripts and clinical notes that can be seamlessly stored in patients' electronic health records. Notetaker complements Tempus' existing mental health platform designed to support clinicians in delivering personalized care. It joins other precision medicine solutions, including the Tempus nP pharmacogenomic test and PRO™, the company's patient reported
The TIME Precision Network is a newly-formed group of investigators across TIME's provider site network dedicated to supporting Phase I trials Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, is leveraging its TIME Network to expand its support in phase I clinical trials. Since its inception in 2019, TIME has supported the rapid patient identification and site activation of clinical trials, bringing cutting-edge trials to patients in communities across the U.S. To further expand its support of phase I trials, Tempus has formed the TIME Precision Network, a group of investigators leading the phase I study platform
The validation study recently published in the Journal of Molecular Diagnostics Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, "Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy" in the Journal of Molecular Diagnostics. Data from this study supports the utility of xF+ as a non-invasive technique to detect actionable variants including resistance mutations, identify clinically relevant biomarkers, and monitor disease progression. The xF+ assay integrates with the Tempus multimodal database, supporting therapeutic recommendations and clinica
The new, proprietary target discovery platform integrates RWD, human biological modeling, and CRISPR screens to accelerate novel target identification Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced Tempus Loop, a new oncology-focused platform for target discovery and validation. Loop is Tempus' proprietary approach to novel target identification that integrates real-world patient data (RWD) with human-derived biological models and CRISPR-screens, all leveraging AI to rapidly uncover insights for pre-clinical therapeutic development. One of the biggest industry challenges has been translating pro
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 abstracts, including one oral presentation, have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, on April 25 - 30 in Chicago. Tempus researchers will showcase scientific and clinical research that highlight the transformative impact of AI on oncology treatment and patient outcomes. "Tempus is proud to showcase a comprehensive collection of scientific research this year, highlighting the impact of our multimodal dataset and AI-enabled diagnostic solutions on cancer research," said Kate
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4680302 Domestic Dial-in Number: (800) 715-9871 International Dial-in Number: (646) 307
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced multi-year, strategic collaborations with AstraZeneca (NASDAQ:AZN) and Pathos AI, Inc., in which the companies will work together to build a multimodal foundation model in oncology which can be used to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the broader oncology community. Tempus' de-identified oncology data will be used to build the foundation model. Upon completion, the model will be shared among all three parties to advance their individual efforts to improve patient care. The agreements i
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of the Tempus Advisory Board. The Tempus Advisory Board is a vital resource for the company in maintaining high standards and ensuring that the strategy and offerings continue to be grounded in expert knowledge from outside the organization. This group of engaged medical professionals is providing guidance, expertise and strategic advice to Tempus on matters related to research, product development, and clinical utility across the various aspects of the company's AI-enabled platform. "Since the beginning, our belief has been that clinical
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services Announced multi-year, strategic collaborations with AstraZeneca and Pathos to work together to build the largest multimodal foundation model in oncology, resulting in additional $200.0 million in data licensing and model development fees over the next
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4680302 Domestic Dial-in Number: (800) 715-9871 International Dial-in Number: (646) 307
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 9601821 Domestic Dial-in Number: (888) 596-4144 International Dial-i
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday, November 4, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The company's conference call that was previously scheduled for November 7, 2024 has been canceled. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Thursday, November 7, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7177136 Domestic Dial-in Number: (800) 715-9871 International Dial-in
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter on Tuesday, August 6, 2024. The company will hold the second quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 6326328 Domestic Dial-in Number: (800) 715-9871 International Dial-in
424B3 - Tempus AI, Inc. (0001717115) (Filer)
10-Q - Tempus AI, Inc. (0001717115) (Filer)
8-K - Tempus AI, Inc. (0001717115) (Filer)
SCHEDULE 13G - Tempus AI, Inc. (0001717115) (Subject)
424B3 - Tempus AI, Inc. (0001717115) (Filer)
8-K - Tempus AI, Inc. (0001717115) (Filer)
DEFA14A - Tempus AI, Inc. (0001717115) (Filer)
DEF 14A - Tempus AI, Inc. (0001717115) (Filer)
PRE 14A - Tempus AI, Inc. (0001717115) (Filer)
144 - Tempus AI, Inc. (0001717115) (Subject)
SC 13G - Tempus AI, Inc. (0001717115) (Subject)
SC 13G - Tempus AI, Inc. (0001717115) (Subject)
SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)
SC 13G - Tempus AI, Inc. (0001717115) (Subject)
SC 13D - Tempus AI, Inc. (0001717115) (Filed by)
4 - Tempus AI, Inc. (0001717115) (Reporting)
BTIG Research initiated coverage of Tempus AI with a rating of Buy and set a new price target of $60.00
Analyst downgraded Tempus AI from Overweight to Neutral and set a new price target of $55.00 from $50.00 previously
William Blair downgraded Tempus AI from Outperform to Mkt Perform
TD Cowen resumed coverage of Tempus AI with a rating of Buy and set a new price target of $74.00 from $58.00 previously
Wolfe Research initiated coverage of Tempus AI with a rating of Outperform and set a new price target of $60.00
Guggenheim initiated coverage of Tempus AI with a rating of Buy and set a new price target of $74.00
Stifel downgraded Tempus AI from Buy to Hold and set a new price target of $65.00 from $45.00 previously
BofA Securities downgraded Tempus AI from Buy to Neutral and set a new price target of $60.00 from $45.00 previously
Piper Sandler initiated coverage of Tempus AI with a rating of Neutral and set a new price target of $40.00
BofA Securities initiated coverage of Tempus AI with a rating of Buy and set a new price target of $41.00